NCT03559972 is a NA clinical trial of on-label facial injection in Facial Photodamage, sponsored by Allergan.

Who is sponsoring NCT03559972?

NCT03559972 is sponsored by Allergan.

What drugs are being tested in NCT03559972?

Interventions in NCT03559972: on-label facial injection.

What condition does NCT03559972 study?

NCT03559972 studies Facial Photodamage.

Is NCT03559972 still recruiting?

NCT03559972 is currently completed. Last updated 30 January 2019.

Last reviewed 2019-01-30 · How we verify

NCT03559972

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections

Completed NA Last updated 30 January 2019

What this trial tests

NA trial testing on-label facial injection in Facial Photodamage in 40 participants. Completed in 3 December 2018.

Timeline

4 June 2018

Primary endpoint
3 December 2018

3 December 2018

Quick facts

Lead sponsor	Allergan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	4 June 2018
Primary completion	3 December 2018
Estimated completion	3 December 2018
Sites	2 locations across United States

Drugs / interventions tested

on-label facial injection

Conditions studied

Facial Photodamage — all drugs for Facial Photodamage →

Sponsor

Allergan — full company profile →

Who can join

30 and older, female only, with Facial Photodamage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the efficacy and tolerability of two topical regimens (containing cosmetic human fibroblast-derived, physiologically-balanced growth factor combination products (HULK and TNS Essential Serum)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Allergan trials

Trials by the same sponsor.

NCT04609020 — Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment · Phase 4 · completed
NCT05452070 — A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft · Phase 3 · completed
NCT05393089 — Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopi · Phase 2 · withdrawn
NCT05152576 — A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants Wi · Phase 2 · completed
NCT05088980 — Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbita · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03559972 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allergan
Last refreshed: 30 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03559972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing